文献速递胸部肿瘤放疗

立体定向体部放疗与手术治疗既往根治性切除术后多原发肺癌的多中心回顾性研究比较

Comparison of stereotactic body radiation therapy versus surgery for multiple primary lung cancers after prior radical resection: A multicenter retrospective study.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-02-15

该多中心回顾性研究纳入203例既往根治性切除术后N0M0、肿瘤直径≤5.0 cm的多原发肺癌患者,比较立体定向体部放疗(SBRT)与再次手术的疗效与安全性。中位随访38.3个月,两组3年局部区域复发率、癌症特异性生存率均无统计学显著差异,SBRT组3级放射性肺炎2.7%,手术组3级并发症3.1%且4例术后90天内死亡。结论认为SBRT是有效且毒性有限的选择,可考虑作为替代治疗。

要点

  • 203例患者中SBRT组73例、手术组130例,中位随访38.3个月。
  • 3年局部区域复发率SBRT组13.1% vs 手术组7.4%(HR 1.97,95%CI 0.74-5.24,P=0.14)。
  • 3年癌症特异性生存率SBRT组88.1% vs 手术组93.8%(HR 1.72,95%CI 0.67-4.44,P=0.23)。

核心结论

  • 对于既往根治性手术切除后的多原发肺癌患者,SBRT是有效且毒性有限的选择,可考虑作为替代治疗。

研究设计与样本

  • 多中心回顾性研究,纳入2013年1月至2020年8月期间来自三个学术癌症中心的203例N0M0、肿瘤直径≤5.0 cm的多原发肺癌患者,SBRT组73例、手术组130例。

主要发现

  • 中位随访38.3个月,SBRT组1年、2年、3年局部区域复发累积发生率分别为5.6%、7.0%、13.1%,手术组分别为3.2%、4.8%、7.4%(HR 1.97,95%CI 0.74-5.24,P=0.14)。
  • SBRT组1年、2年、3年癌症特异性生存率分别为95.9%、94.5%、88.1%,手术组分别为96.9%、94.6%、93.8%(HR 1.72,95%CI 0.67-4.44,P=0.23)。
  • SBRT组2例(2.7%)发生3级放射性肺炎;手术组4例(3.1%)发生3级并发症,4例在术后90天内死于肺炎或肺心病。

关键数值与推荐

  • 主要终点为3年局部区域复发和治疗相关毒性。
  • SBRT组3年局部区域复发率13.1% vs 手术组7.4%(HR 1.97,95%CI 0.74-5.24,P=0.14),差异未达统计学显著。
  • SBRT组3年癌症特异性生存率88.1% vs 手术组93.8%(HR 1.72,95%CI 0.67-4.44,P=0.23),差异未达统计学显著。

临床怎么用

  • 作者认为,对于既往根治性手术切除后的多原发肺癌患者,SBRT是有效且毒性有限的选择,可考虑作为替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who previously underwent surgical resection of initial primary lung cancer are at a high risk of developing multiple primary lung cancers (MPLCs). The purpose of this study was to compare the efficacy and safety between stereotactic body radiation therapy (SBRT) and surgery for MPLCs patients after prior radical resection for the first lung cancers. METHODS: In this multicenter retrospective study, eligible MPLC patients with tumor diameter of 5.0 cm or less at N0M0 who underwent SBRT or reoperation between January 2013 and August 2020 were enrolled. The primary endpoint was the 3-year locoregional recurrence and treatment-related toxicity. Kaplan-Meier method was used to calculate survival rates. The χ2 test was adapted to assess the difference of categorical variables between the two subgroup patients. RESULTS: A total of 203 (73 in the SBRT group and 130 in the surgery group) patients from three academic cancer centers were evaluated with a median follow-up of 38.3 months. The cumulative 1-, 2-, and 3-year incidences of locoregional recurrence were 5.6 %, 7.0 % and 13.1 % in the SBRT group versus 3.2 %, 4.8 % and 7.4 % in the surgery group, respectively [hazard ratio (HR), 1.97; 95 % confidence interval (CI), 0.74-5.24; P = 0.14]. The cancer-specific survival rates were 95.9 %, 94.5 % and 88.1 % versus 96.9 %, 94.6 % and 93.8 % in the SBRT and surgery groups respectively (HR, 1.72; 95 % CI, 0.67-4.44; P = 0.23). In the SBRT group, two patients (2.7 %) suffered from grade 3 radiation pneumonitis, while in the surgery group, grade 3 complications occurred in four (3.1 %) patients, and four cases were expired due to pneumonia or pulmonary heart disease within 90 days after surgery. CONCLUSIONS: SBRT is an effective therapeutic option with limited toxicity compared to surgery for patients with MPLCs after prior radical surgical resection, and it could be considered as an alternative treatment for those patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dong B, Chen R, Zhu X, et al. Comparison of stereotactic body radiation therapy versus surgery for multiple primary lung cancers after prior radical resection: A multicenter retrospective study. Clin Transl Radiat Oncol. 2023. PMID: 36936471. doi:10.1016/j.ctro.2023.100601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。